Notice: This company has been marked as potentially delisted and may not be actively trading. BioTelemetry (BEAT) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends Get the Latest News and Ratings for BEAT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for BioTelemetry and its competitors. Enter your email to sign up for newsletter Sign Up BEAT Analyst Ratings Over TimeTypeCurrent Forecast11/24/23 to 11/23/241 Month Ago10/25/23 to 10/24/243 Months Ago8/26/23 to 8/25/241 Year Ago11/24/22 to 11/24/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)2 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.00$8.00$8.00$6.78Forecasted Upside186.74% Upside247.83% Upside240.43% Upside394.49% UpsideConsensus RatingBuyBuyBuyBuy “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! BEAT Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BEAT Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table BioTelemetry Stock vs. The CompetitionTypeBioTelemetryMedical CompaniesS&P 500Consensus Rating Score 3.00 2.80 2.50Consensus RatingBuyModerate BuyModerate BuyPredicted Upside186.74% Upside27,098.21% Upside7.66% UpsideNews Sentiment RatingNeutral NewsSee Recent BEAT NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/15/2024Benchmark3 of 5 starsW. SutherlandSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$8.00 ➝ $8.00+252.42%5/19/2023Alliance Global Partners1 of 5 stars Lower Target$10.00 ➝ $5.55+151.13%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:55 PM ET. BEAT Forecast - Frequently Asked Questions What is BioTelemetry's forecast for 2025? According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for BioTelemetry is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. Should I buy or sell BioTelemetry stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BEAT shares. Does BioTelemetry's stock price have much upside? According to analysts, BioTelemetry's stock has a predicted upside of 186.74% based on their 12-month stock forecasts. What analysts cover BioTelemetry? BioTelemetry has been rated by research analysts at Benchmark in the past 90 days. Do Wall Street analysts like BioTelemetry more than its competitors? Analysts like BioTelemetry more than other "medical" companies. The consensus rating for BioTelemetry is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BEAT compares to other companies. Stock Forecasts and Research Tools Related Companies ANIK Stock Forecast LUNG Stock Forecast OBIO Stock Forecast CATX Stock Forecast INFU Stock Forecast SGHT Stock Forecast ARAY Stock Forecast PROF Stock Forecast SKIN Stock Forecast NVRO Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here This page (NASDAQ:BEAT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioTelemetry, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioTelemetry With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
